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Abstract
Atrial fibrillation (AF) is one of the most common arrhythmias seen in clinical practice. Current
evidence suggests that serum uric acid (SUA) could be a marker of oxidative damage a factor
reported as part of the mechanisms of AF. The purpose of this study was to evaluate if SUA
predicted AF in the Atherosclerosis Risk in Communities study (ARIC). This analysis included
15,382 AF-free black and white men and women, aged 45-64, from the ARIC study, a population-
based prospective cohort in the US. SUA was determined using the uricase-peroxidase method at
baseline. The primary outcome was the incidence of AF defined as the occurrence of AF detected
from hospital discharge codes, scheduled study electrocardiograms (ECG) and /or death
certificates during follow-up period (1987-2004). We identified 1085 cases of incident AF. In Cox
proportional hazards models adjusted for age, sex, race, center, education, body-mass index,
serum glucose, systolic and diastolic blood pressure, LDL cholesterol, alcohol use, prevalent
coronary heart disease and heart failure, serum creatinine, use of diuretics, and p wave duration on
the ECG (as a measure of left atrial size) at baseline, the hazard ratio (HR) of AF associated with a
1-standard deviation increment in SUA was 1.16; 95% CI 1.06 -1.26. The association of SUA with
AF risk differed by race and gender (p for interaction<0.01). In conclusion, elevated SUA is
associated with a higher risk of AF, particularly among blacks and women. Further studies should
replicate this association and explore potential mechanisms.
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Serum uric acid (SUA) is a by-product of purine catabolism, the terminal steps of which are
catalyzed by xanthine oxidoreductase (XOR). SUA as an independent predictor of
cardiovascular diseases and mortality1, 2. The rationale for this association is that SUA
levels rise due to increased purine catabolism resulting from tissue hypoxia and apoptosis
and this excess leads to the formation of reactive oxygen species (ROS) capable of oxidative
stress damage 3. Therefore, SUA might be an inexpensive marker of the effects of oxidative
stress on the heart 4, 5. We hypothesized that in a population-based study of middle aged
men and women from four United States communities, those with elevated SUA at baseline
are at increased risk for the development of future AF and that this association is
independent of cardiovascular risk factors.
Methods
The ARIC Study is a longitudinal community-based cohort of 15,792 men and women
adults aged 45 to 64 years at enrollment. The cohort was sampled from 4 US communities:
Forsyth County, North Carolina; Jackson, Mississippi; the northwest suburbs of
Minneapolis, Minnesota; and Washington County, Maryland. By design, the Jackson site
exclusively recruited African Americans, thereby accounting for 90% of African Americans
in the study. Most of the remaining African Americans came from Forsyth County. The
sampling procedures and methods used in ARIC have been described in detail elsewhere 6.
Baseline visits were conducted from 1987 through 1989.
Participants were followed up subsequently by annual telephone interviews and three field
center visits every 3 years (last one in 1996-98). For this study, participants were excluded
for the following reasons: electrocardiogram (ECG) diagnosed AF at baseline (n=37),
missing SUA measurement at baseline (n= 128), and absent ECG examination (n=245). This
left 15,382 ARIC participants for analysis.
Participants were asked to fast for at least 12 hours before morning blood collection. After
applying a tourniquet, blood was drawn from the antecubital vein while participants were
seated. Blood specimens were collected into vacuum tubes containing serum-separator gel
(glucose, creatinine and SUA) and EDTA (lipids). Tubes were centrifuged at 3000g for 10
minutes at 4°C. After separation, aliquots were quickly frozen at -70°C until analysis was
performed (within a few weeks). Uric acid was measured using the uricase-peroxidase
enzymatic method. The reliability coefficient of SUA was 0.91 assessed by repeated
measurements taken ≥1 week apart in 40 subjects (10 per ARIC center) and within person
variability was 7.2% [13]. SUA was measured at baseline (n= 15,646) and at visit 2 (n=
14,296).
AF diagnoses were obtained from 3 sources: ECGs at the 4 scheduled study exams through
1998, hospital discharge records through 2004, and death certificates through 2004. Study
participants underwent standard 12-lead ECG recordings at baseline and at each of the three
follow-up exams. All ECG recordings were done with MAC PC Personal Cardiographs
(Marquette Electronics, Inc, Milwaukee, WI). All ECG recordings automatically coded as
AF were visually rechecked to confirm the diagnosis 7.
As part of standard follow-up procedures in ARIC, a trained abstractor obtained and
recorded all International Classification of Diseases, Ninth Revision (ICD-9) hospital
discharge diagnoses codes from each participant’s hospitalizations reported in the annual
follow-up interview or via hospital surveillance. AF was defined as the presence of ICD-9
code 427.31 in the discharge codes. Participants with a diagnosis of atrial flutter (ICD-9
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code 427.32) not developing AF in subsequent follow-up were not considered as having AF
(n = 53) and their follow-up time was continued until censored. Transient AF can occur
during cardiac operative procedures. Therefore, we excluded transient AF occurring
simultaneously with heart revascularization surgery (ICD-9 code 36.X) or other cardiac
surgery involving heart valves or septa (ICD-9 code 35.X), without evidence of AF in
subsequent hospitalizations or study exams (n = 86 cases) and their follow-up time was
continued until censored. Participants were also labeled as AF cases if the underlying cause
of death was AF (ICD-10 code I48 or ICD-9 code 427.3). A validation study of the AF ICD
code in a sample of ARIC hospitalizations reported a sensitivity and positive predictive
values close to 90% 8.
The incidence date of AF was defined as the date of the first ECG showing AF, the first
hospital discharge with an AF or atrial flutter diagnosis (the latter only if AF was identified
later in the same patient), or death certificate with AF, whichever occurred earlier.
Additional variables were collected at visit 1 (baseline). Information on age, sex, race,
educational attainment, alcohol and cigarette use, and physical activity were based on self-
report. Other variables like blood pressure and body mass index were measured. Serum
creatinine, glucose and triglycerides were measured. Use of diuretics within the two weeks
before the baseline interview were identified from medication containers and used as a
categorical variable. Metabolic syndrome was defined according to the National Cholesterol
Education Program 9.
Prevalent heart failure was defined as current use of medications for heart failure at the
baseline exam or evidence of manifest heart failure, stage 3, according to the Gothenburg
criteria 10. Prevalent MI was defined as self-reported history of physician-diagnosed MI,
silent MI by electrocardiography, or hospitalized MI at baseline.
Incidence of cardiovascular events was collected during the follow-up. Incident heart failure
(HF) cases were identified through review of death certificates and local hospital discharge
lists and defined according to the International Classification of Diseases Codes (ICD-9 or
ICD-10). Incident HF was defined as first HF hospitalization (428, ICD-9) or any death
where the death certificate included an HF code (428, ICD-9 and I50, ICD-10). Non-
hospitalized, nonfatal HF was not captured. Hospitalized MI was defined according to ARIC
standardized criteria 11.
Follow-up started the date of first examination and ended at the development of AF, death,
lost to follow-up, or December 31, 2004 (whatever occurred earlier). Incidence rates were
calculated for each quartile of SUA dividing the number of incident AF cases over the
person-years of follow-up. We calculated the hazard ratio (HR) of developing AF per 1
standard deviation (SD) of SUA using Cox proportional hazards models, adjusting for
potential confounding factors. We also evaluated the association of quartiles of SUA with
AF incidence creating dummy variables and using the lowest quartile of SUA as the
reference in Cox proportional hazards models. We conducted a chi-square goodness of fit
test and adjusted our analysis adjusted for age, gender, education, race, center, body mass
index, alcohol use, serum glucose, systolic and diastolic blood pressure, low density
lipoprotein (LDL) cholesterol, prevalent coronary heart disease and heart failure, serum
creatinine, use of diuretics and p wave duration on ECG at baseline. To assess the robustness
of our analysis we performed two subsidiary analyses. First, we calculated the mean SUA
level using the first (baseline) and second (visit 2) measurements and determined event rates
and hazard ratios. Second, SUA was used as a time varying covariate in the multivariate Cox
proportional hazards models. Finally, we included interaction terms to evaluate if the
association between AF and SUA differed by race, gender, or the metabolic syndrome.
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Because SUA might increase the risk of AF through an increased risk of heart failure or
myocardial infarction, we conducted an additional analysis censoring individuals when they
developed heart failure or myocardial infarction before they developed AF.
Proportional hazard assumptions and assumptions of linearity of the association were
examined using scaled Schoenfeld residuals. Analyses were performed using STATA
version 10 (College Station, TX) and all tests were two-tailed with p value of <0.05
considered as statistically significant.
Results
Selected baseline characteristics of the cohort of 15,382 adults free of AF are shown by
quartiles of baseline SUA in Table 1. Participants in the highest quartile of SUA were more
likely to be older, black, males and had a higher prevalence of cardiovascular risk factors,
incident heart failure and myocardial infarction when compared to participants in the lowest
quartile of SUA.
We identified 1085 participants with incident AF over a median follow-up of 16.8 years.
Incident AF was positively associated with SUA levels, with an AF rate of 3 per 1000
person-years in the lowest quartile of SUA vs. 8 per 1000 person-years in the highest
quartile (p<0.01) (table 2). This nearly three-fold risk increment persisted when we used the
mean SUA of visits 1 and 2 as the main exposure (p<0.01).
Table 3 shows the adjusted relationship between baseline SUA and incident AF. After
simultaneous adjustment for age, sex, race, education, field center, body-mass index, alcohol
use, serum glucose, systolic and diastolic blood pressure, LDL cholesterol, prevalent heart
failure, prevalent coronary heart disease, serum creatinine, p wave duration on ECG (as a
measure of left atrial size) at baseline and use of diuretics, SUA was significantly associated
with the subsequent risk of incident AF (HR of 1.16; 95% CI 1.06 -1.26 per 1 SD increase).
Similar risk associations were seen using the mean value of SUA between visit 1 and visit 2
and in analysis including SUA as a time varying exposure. When stratified by ARIC
recruitment center only the Jackson site and the Minneapolis site had a significant
association between SUA and AF.
When censoring individuals at the time of developing incident heart failure and myocardial
infarction the relation between SUA and AF was attenuated, with a HR of 1.07 (95% CI
0.97-1.17) per 1 SD increase. Similar risk gradients were seen for mean value of SUA
between visit 1 and visit 2 and the time varying analysis (table 3).
Figure 1 shows the incidence of AF by quartile over time. Using the baseline measurement
of SUA those in the highest quartile (>7.1 mg/dl) had a HR of AF of 1.41 (95% CI 1.11
-1.80) when compared to those in the lowest quartile (<5.0 mg/dl).
Baseline SUA was associated with incident AF in blacks (HR per 1 SD difference 1.56; 95%
CI 1.28-1.90) but not in whites (HR 1.05 per 1 SD difference; 95% CI 0.95-1.11) (p for
interaction<0.01), in women (HR 1.25 per 1 SD difference; 95% CI 1.08-1.43) but not in
men (HR 1.05 per 1 SD difference; 95% CI 0.94-1.18) (p for interaction=0.01). The
association of SUA with incident AF was similar in participants with metabolic syndrome
(HR per 1 SD 1.18; 95% CI 1.03-1.33) and those without metabolic syndrome (HR per 1 SD
difference 1.10; 95% CI 0.97-1.23) (p for interaction=0.24) after adjustment for other
covariates.
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We report that SUA is independently and associated with incident AF in the ARIC cohort.
This relationship was graded and independent of a wide range of established AF risk factors
and differed by race and sex. Strengths of the study that lend weight to these conclusions are
its prospective design, large community-based sample, and carefully standardized
assessments.
Several population based studies have found SUA to be an independent marker of CVD
disease 1, 12, however, other studies have found that the association is potentially explained
by the cardiovascular risk factor load 13. A prior case-control study reported an association
between permanent AF and SUA 14. A potential explanation for this association is the link
between SUA and oxidative stress 4, 5. SUA is a by-product of purine catabolism, the
terminal steps of which are catalyzed by xanthine oxidoreductase (XOR). XOR is a major
source of ROS production which has been found to be elevated in both animal and human
left atria with AF 15. Animal studies have shown that oxidative stress leads to the
development of atrial electrical remodeling 16, which in turn results in reentry and a
decrease in nitric oxide production leading to S-nitrosylation of ion channels that can
shorten the plateau phase of the action potential causing accelerated repolarization and
AF 17, 18.
In humans, cross-sectional and case-control studies have consistently reported associations
between markers of oxidative stress and valvular and post-CABG related AF. In patients
with AF after radiofrequency ablation, ROS markers had a strong, graded relationship to the
recurrence of paroxysmal AF after 4 years of follow-up 19. Also, a recent study found an
association between NADPH and incident AF in consecutive elective patients undergoing
coronary artery bypass grafting 20.
Besides oxidative stress, there are other potential epidemiological explanations for an
association between SUA and AF. First, SUA could potentially be a marker of
cardiovascular risk factor burden 21, and even though we found that the relationship with AF
was independent of most cardiovascular risk factors, the potential for residual confounding
by not accounting for factors like inflammatory markers could explain our results. Also,
SUA is a marker of endothelial dysfunction, metabolic syndrome and diabetes 21, all of
which are important predictors of AF. Finally, the important attenuation of HRs after
censoring for the occurrence of myocardial infarction or heart failure, indicates that the
association between SUA and AF could be partially explained by increased risk of other
cardiovascular diseases. Because of the long follow-up and likely progression of heart
disease over time our intent with this analysis was to account for the effect that incident
heart failure and myocardial infarction could have as mediators on incident atrial fibrillation.
We found that SUA was associated with AF in Blacks but not Whites. This racial
heterogeneity has been reported in other ARIC studies for other diseases and its
correlates 22, 23. Higher uric acid levels have been found in Blacks because of higher
prevalence of SLC2A9, a gene, related to the re-absorption of uric acid in the proximal
tubule 24. The higher SUA levels, could potentially lead to endothelial dysfunction and the
activation of the renin-angiotensin 25 system which could potentially end in AF. However, a
clear mechanism for the race and gender differences is yet to be determined.
Nonetheless, several limitations deserve mention. First, the current analysis is based on one
or two measurements of SUA and the impact of the change in SUA levels on incidence of
AF over time is unknown. However, our analysis included a time varying evaluation of SUA
over 3 years and the results were similar to the single or multiple averaged measurements.
Second, potential unmeasured confounders not adjusted for, such as kidney function, could
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explain our results. Though we were able to adjust for blood creatinine levels, we lacked
data on albuminuria and hematuria, and hence ARIC participants with normal glomerular
filtration rate and kidney damage evidenced by these signs could have been misclassified as
having normal kidney function. However, this number is expected to be small. Third, the
method of AF ascertainment could lead to lower identification rates of outpatient AF cases
and our hospital-based AF ascertainment could lead to some false positives. In the ARIC
cohort we were able to confirm only 89% of AF events in a sample of 125 discharge
summaries. However, the AF incidence and lifetime risk in the white ARIC participants
were similar to those from other populations, such as the Mayo Clinic study in Olmsted
County, Minnesota, Cardiovascular Health Study or the Framingham Heart Study 8, 26-28.
In summary, we have found that SUA might be an independent risk factor for AF,
suggesting that oxidative stress could play an important role in the development of AF.
Whether modification of SUA might influence AF risk awaits further study.
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Survival free of atrial fibrillation by quartile of SUA*, The Atherosclerosis Risk in
Communities study, 1987-2004.
* Quartile 1 <5.0 mg/dl, Quartile 2 5.0-5.9 mg/dl, Quartile 3 6.0-7.0 mg/dl, Quartile 4 >7.0
mg/dl
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Table 2
Incidence rates and hazard ratios of atrial fibrillation by quartile of serum uric acid
Quartile of SUA Number at risk Number developing AF Incidence rate of AF per
1000 person-years
Age, gender and race-adjusted
HR (95% C.I)
Baseline quartiles
Quartile 1 (<5.0 mg/dl) 3880 186 3 1 (Reference)
Quartile 2 (5.0-5.9 mg/dl) 3919 243 4 1.04(0.83-1.30)
Quartile 3 (6.0-7.0 mg/dl) 3927 297 5 1.30(1.04-1.62)
Quartile 4 (>7.0 mg/dl) 3656 359 8 1.74(1.39-2.17)
p for trend <0.01 <0.01
Mean quartiles *
Quartile 1 (<5.0 mg/dl) 3584 158 3 1 (Reference)
Quartile 2 (5.0-5.9 mg/dl) 3461 213 4 1.29(1.02-1.63)
Quartile 3 (6.0-7.0 mg/dl) 3390 250 5 1.40(1.11-1.78)
Quartile 4 (>7.0 mg/dl) 3448 319 7 2.00(1.58-2.52)
p for trend <0.01 <0.01
*
Excludes cases of AF between visits 1 and 2 and those who did not attend visit 2.
HR: Hazard ratio, CI: confidence interval
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